BioXcel Therapeutics 9.75 million Settlement Over Alleged False TRANQUILITY II Trial Claims

BioXcel Therapeutics and certain executives agreed to pay $9.75 million to resolve a securities class action that accused them of making materially false and misleading statements about the TRANQUILITY II clinical trial and their compliance with trial protocols and FDA regulations. The suit covers investors who bought BioXcel stock between March 9 and June 28, 2023; plaintiffs say the alleged misstatements artificially inflated the share price and caused losses when the truth emerged. The company denied wrongdoing but settled to avoid the expense and uncertainty of prolonged litigation, and the court-approved distribution will pay claimants pro rata — estimated average recoveries were reported at about $1.52 per share before deductions and roughly $1.10 per share net after fees. The case fits a broader pattern of investor litigation in the biopharma sector, where disclosure about trial design, compliance with protocol and FDA oversight can move markets and prompt suits under securities laws (including Rule 10b-5) when expectations are upended. Regulators expect companies to follow Good Clinical Practice and accurate public reporting, and repeated lawsuits have pushed firms to tighten internal controls, counsel carefully on forward-looking statements, and improve quality-assurance for trials. For investors and executives alike, these settlements underscore the financial and reputational risks tied to clinical-trial communications and regulatory compliance.